Our data did not show differences in the CD19+ subpopulations, but we observed a reduction in the percentage of the CD3+ cells in SCD patients (40.9% vs. 49.2%, p-value ≤.01). This evidence concerns the gene CD19 and Schnyder corneal dystrophy.